Indivior to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Indivior (Nasdaq: INDV) will participate in two investor conferences in Miami in March 2026. CEO Joe Ciaffoni will host 1x1 and group meetings at Barclays 28th Annual Global Healthcare Conference on March 10, 2026 and at Jefferies Biotech on the Beach Summit on March 11, 2026.
Mr. Ciaffoni will join a public fireside chat on March 10 at 2:00 p.m. U.S. EST; interested investors should contact their Barclays or Jefferies representative to schedule meetings. The fireside chat will be available via webcast.
Details
News Market Reaction – INDV
On Feb 24, the day this news came out, INDV closed 0.39% above the previous close.
Data tracked by StockTitan Argus for the Feb 24 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences:
- Barclays 28th Annual Global Healthcare Conference – Miami, FL
Joe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th. Joe Ciaffoni will also participate in a fireside chat on Tuesday, March 10th at 2:00 p.m. U.S. EST. Interested investors should contact their Barclays representative to schedule a meeting. The fireside chat will be publicly available and can be accessed using the following weblink: Barclays Webcast Link.
- 2026 Jefferies Biotech on the Beach Summit – Miami, FL
Joe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Wednesday, March 11th. Interested investors should contact their Jefferies representative to schedule a meeting.
About Indivior
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit https://www.indivior.com/ to learn more. Connect with Indivior on LinkedIn by visiting https://www.linkedin.com/company/indivior.
For Further Information
Investors:
Jason Thompson
Indivior Pharmaceuticals
Tel: 804-402-7123
E-mail: jason.thompson@indivior.com
Media:
Cassie France-Kelly
Indivior Pharmaceuticals
Tel: 804-594-0836
E-Mail: Indiviormediacontacts@indivior.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.